Contact
Please use this form to send email to PR contact of this press release:
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
TO:
Please use this form to send email to PR contact of this press release:
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial
TO: